When complaints of dizziness in elderly patients were evaluated in primary care offices, the most common cause was cardiovascular disease, combined with contributions from adverse drug reactions. This contradicts many previous studies done in tertiary care settings where vertigo or vestibular disease was found to be the most common cause.
Vital exhaustion predicts long-term risk for adverse cardiac events in men and women, independent of established biomedical risk factors.
A new three-drug antihypertensive pill, combining an angiotensin II receptor antagonist (olmesartan [OLM]), a calcium channel blocker (amlodipine [AML]), and a thiazide diuretic (hydrochlorothiazide [HCTZ]), has been approved by the FDA. The new combination is marketed by Daiichi Sankyo as Tribenzor.
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
In a sample of patients from primary care practice, a single screening question accurately identified drug use.
